Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line systemic anti-cancer therapy for the treatments of resectable gastric or gastro-oesophageal junction adenocarcinoma: SMC2944

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT Dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Durvalumab in combination with fluorouracil + docetaxel + folinic acid + oxaliplatin (FLOT) for the treatment of adults with resectable gastric or gastro-oesophageal junction (GEJ) adenocarcinoma (SMC2944) is being assessed for use by NHS Scotland.

The aim of this work was to capture real-world evidence (RWE) from NHS Scotland on the use of systemic anti-cancer therapy (SACT) for the first-line treatment of adults with resectable gastric or GEJ adenocarcinoma. Details of the presumptions made to identify this cohort are described in Section 2.3.1 in the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2944, to patients in Scotland.

The objectives were to:

• Determine the number of patients prescribed SACT for the first-line treatment of resectable gastric or GEJ adenocarcinoma.
• Describe the baseline characteristics of patients prescribed SACT for the first-line treatment of resectable gastric or GEJ adenocarcinoma.
• Describe the baseline characteristics of patients prescribed FLOT for the first-line treatment of resectable gastric or GEJ adenocarcinoma.